CytomX Therapeutics Inc. (CTMX)
NASDAQ · Healthcare
CytomX Therapeutics Inc. EBITDA 2013–2025
CytomX Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2013 to 2019. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- CytomX Therapeutics Inc. ebitda for the quarter ending March 31, 2019 was -15.9 M, a 4.55% increase year-over-year.
- CytomX Therapeutics Inc. ebitda for the twelve months ending March 31, 2019 was -64.4 M, a 16.98% increase year-over-year.
- CytomX Therapeutics Inc. annual ebitda for 2018 was -76.0 M, a 70.33% increase from 2017.
- CytomX Therapeutics Inc. annual ebitda for 2017 was -44.6 M, a 22.88% decrease from 2016.
- CytomX Therapeutics Inc. annual ebitda for 2016 was -57.9 M, a 80.81% increase from 2015.
- CytomX Therapeutics Inc. annual ebitda for 2015 was -32.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
CytomX Therapeutics Inc. EBITDA — FAQ
CytomX Therapeutics Inc. (CTMX) ebitda over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CTMX's ebitda history?
The chart and table above show CytomX Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.